PCI Pharma Services announces multi-million expansion of UK manufacturing facility
The CDMO will add two new facilities to support its high potency manufacturing services
PCI Pharma Services announced plans for a multi-million dollar expansion of its facility in Tredegar, UK on Wednesday, in response to increasing demand for high potency manufacturing services in the oncology space.
The Contract Development and Manufacturing Organisation (CDMO) will add two new facilities dedicated to the manufacturing and packaging of solid oral-dose tablets and capsules to the site.
A contained manufacturing building (CMF2) will double large-scale processing capacity including dispensing and fluid bed granulation of high-potency solid-dose products at commercial scale. This is based on the company’s original CMF1, which opened in 2013. PCI will also launch a new high-potency, multi-product packaging facility with primary and secondary blistering and bottling suites.
Speaking about the news, PCI Pharma Services CEO Salim Haffar said the expansion would ‘address the growing and urgent need for specialty global manufacturing services within the oncology arena.’
‘As the market expands for potent therapies and highly complex, concentrated formulations that can present unique challenges to manufacturing and packaging, we’re proud to be one of the few providers with the global capabilities to manage this specialty at both clinical and importantly, commercial scale,’ he said.
Both facilities will contain state-of-the-art equipment, including a replica of CMF1’s large-scale granulation suite and a down-flow booth with containment screening.
The expansion is expected to create up to 40 new jobs in the first year and more as the facilities scale up. PCI currently employs close to 500 people at the Tredegar site.
Related News
-
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines. -
News Moderna sues Pfizer/BioNTech over COVID-19 vaccine patent infringement
The pharmaceutical companies behind the leading COVID-19 vaccines are in a legal dispute over intellectual property rights surrounding the mRNA vaccines that were released after emergency use authorization in December 2020. -
News Accepting novel excipients for innovative drug development
With the rapid development and manufacturing of new drugs and therapeutics being pushed through the pipeline, excipient manufacturers are navigating a challenging landscape to meet the demand for new and novel excipients. -
News ChargePoint Technology acquires PuroVaso for greater range of powder and liquid transfer solutions
ChargePoint Technology has acquired PuroVaso, leader in the design, development, and manufacture of single-use containers, handling equipment, and accessories for pharma, biopharma, and life sciences. -
News Lonza adds X-ray powder diffraction to micronisation portfolio in Monteggio (CH)
Lonza expands solid-state characterisation services for polymorph and solid-state properties of APIs with the addition of X-ray powder diffraction to its portfolio.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance